LABORATORY RESEARCH Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry Researchers found that replication protein A (RPA)-RAD51 exchange requires the BRCA2 partner DSS1. Biochemical, structural, and in vivo analyses reveal that DSS1 allows the BRCA2-DSS1 complex to physically and functionally interact with RPA. [Mol Cell] Abstract | Graphical Abstract | Press Release Decreased LRIG1 in Fulvestrant-Treated Luminal Breast Cancer Cells Permits ErbB3 Upregulation and Increased Growth LRIG1 overexpression improved fulvestrant-mediated growth inhibition, whereas cells expressing the LRIG1 mutant were poorly sensitive to fulvestrant, despite effective ERα downregulation. [Oncogene] Abstract RING Finger Protein 31 Promotes p53 Degradation in Breast Cancer Cells RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 signaling as a potential RNF31 target. RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner. [Oncogene] Full Article IL-17A and Its Homologs IL-25/IL-17E Recruit the c-RAF/S6 Kinase Pathway and the Generation of Pro-Oncogenic LMW-E in Breast Cancer Cells Investigation of the molecular signaling following stimulation of human breast cancer cell lines with IL-17A and IL-17E showed that both cytokines induced the phosphorylation of c-RAF, ERK1/2 and p70 S6 kinase were involved in the proliferation and survival of tumor cells. [Sci Rep] Full Article The Chemomodulatory Effects of Resveratrol and Didox on Herceptin Cytotoxicity in Breast Cancer Cell Lines The authors investigated the influence of resveratrol and didox on the cytotoxicity profile of herceptin in HER-2 receptor positive and HER-2 receptor negative breast cancer cell lines [Sci Rep] Full Article Estrogen Receptor α Regulates Non-Canonical Autophagy that Provides Stress Resistance to Neuroblastoma and Breast Cancer Cells and Involves BAG3 Function Researchers characterized tumor cell lines ectopically expressing estrogen receptor (ER)α or ERβ as well as the breast cancer-derived MCF-7 cell line endogenously expressing ERα but being ERβ negative. [Cell Death Dis] Full Article Histone Deacetylase Inhibitor Entinostat in Combination with a Retinoid Downregulates HER2 and Reduces the Tumor Initiating Cell Population in Aromatase Inhibitor-Resistant Breast Cancer Scientists investigated whether combining all-trans retinoic acid and histone deacetylase inhibitor entinostat can inhibit tumor initiating cells and HER2 in aromatase inhibitor-resistant cells and tumors. [Breast Cancer Res Treat] Abstract Extracellular Vesicles from Women with Breast Cancer Promote an Epithelial-Mesenchymal Transition-Like Process in Mammary Epithelial Cells MCF10A The authors studied whether extracellular vesicles from plasma of women with breast cancer are able to induce an epithelial-mesenchymal transition process in mammary epithelial cells MCF10A. [Tumor Biol] Abstract Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells When grown in suspension culture, MCF10A cells showed low mammosphere-forming ability. Cells in mammospheres and three-dimensional (3D) culture expressed both luminal and basal markers. The acinar structure formed by MCF10A cells in 3D culture was positive for both basal markers and the milk proteins β-casein and α-lactalbumin. [PLoS One] Full Article CLINICAL RESEARCH Phase I/II Trial of Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple-Negative Breast Cancer Investigators evaluated the feasibility and efficacy of adding sunitinib to paclitaxel/carboplatin in the neoadjuvant therapy of patients with triple-negative breast cancer. [Breast Cancer Res Treat] Abstract Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers Researchers analyzed the effects of methods of risk estimation and bias correction and of population factors on cumulative lifetime risks in this retrospective clinical cohort of BRCA1/2 carriers. [J Clin Oncol] Abstract |